Abstract
Objective Electrical deep brain stimulation (DBS) is an established treatment for patients with drug-resistant epilepsy. Sleep disorders are common in people with epilepsy, and DBS may actually further disturb normal sleep patterns and sleep quality. Novel devices capable of DBS and continuous intracranial EEG (iEEG) telemetry enable detailed assessments of therapy efficacy and tracking sleep related comorbidities. Here, we investigate the feasibility of automated sleep classification using continuous iEEG data recorded from Papez’s circuit in four patients with drug resistant mesial temporal lobe epilepsy using an investigational implantable sensing and stimulation device with electrodes implanted in bilateral hippocampus (HPC) and anterior nucleus of thalamus (ANT).
Approach The iEEG recorded from HPC is used to classify sleep during concurent DBS targeting ANT. Simultaneous polysomnography and HPC sensing were used to train, validate and test an automated classifier for a range of ANT DBS frequencies: no stimulation, 2 Hz, 7 Hz, and high frequency (>100 Hz).
Main results We show that it is possible to build a patient specific automated sleep staging classifier using power in band features extracted from one HPC sensing channel. The patient specific classifiers performed well under all thalamic DBS frequencies with an average F1-score 0.894, and provided viable classification into awake and major sleep categories, rapid eye movement (REM) and non-REM. We retrospectively analyzed classification performance with gold-standard polysomnography annotations, and then prospectively deployed the classifier on chronic continuous iEEG data spanning multiple months to characterize sleep patterns in ambulatory patients living in their home environment.
Significance The ability to continuously track behavioral state and fully characterize sleep should prove useful for optimizing DBS for epilepsy and associated sleep, cognitive and mood comorbidities.
- Electrical Brain Stimulation
- Deep Brain Stimulation
- Implantable Devices
- Automated Sleep Scoring
- Ambulatory intracranial EEG
- Epilepsy
Competing Interest Statement
GW, BB, JVG, and BL are named inventor for intellectual property developed at Mayo Clinic and licensed to Cadence Neuroscience Inc. BNL royalties are waived to his Mayo Clinic research account. GW has licensed intellectual property developed at Mayo Clinic to NeuroOne, Inc. BL, GW, and NG in an investigator for the Medtronic Deep Brain Stimulation Therapy for Epilepsy Post-Approval Study (EPAS). VK consults for Certicon a.s. IB has received compensation from an internship with Cadence Neuroscience Inc., for work unrelated to the current publication. Mayo Clinic has received research support and consulting fees on behalf of GW, BNL and BB from UNEEG, NeuroOne Inc., Epiminder, Medtronic Plc., and Philips Neuro.
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT03946618
Funding Statement
This work was supported by NIH Brain Initiative UH2&3 NS095495 Neurophysiologically-Based Brain State Tracking & Modulation in Focal Epilepsy, DARPA HR0011-20-2-0028 Manipulating and Optimizing Brain Rhythms for Enhancement of Sleep (Morpheus), Mayo Clinic, and Medtronic Inc. Medtronic provided the investigational Medtronic Summit RC+STM devices. V.K. was partially supported by institutional funding of Czech Technical University in Prague, Czech Republic.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This human subjects research study was carried out under an FDA IDE: G180224 and Mayo Clinic IRB: 18-005483 "Human Safety and Feasibility Study of Neurophysiologically Based Brain State Tracking and Modulation in Focal Epilepsy".
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵+ co-first authors
Data Availability
Data is available upon reasonable request.
